Articles from GUERBET

Adjustment of 2025 financial targets

Revenue at September 30, 2025

H1 2025 results

Change in General Management

Adjustment of 2025 full-year financial targets

H1 2025 revenue

2024 full-year results

2024 revenue

Revenue at September 30, 2024

H1 2024 results

H1 2024 revenue

The CHMP issues an opinion in favour of granting an EU marketing authorisation for Elucirem™ (Gadopiclenol)with the indication of use for magnetic resonance imaging with contrast enhancement in adults and children aged 2 years and over

Half-year results 2023

Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer

Q1 2023 RevenueQuarterly activity

2022 revenue

2023 Strategic Priorities

Guerbet announces a change in governance for its Artificial Intelligence projects

Revenue on September 30, 2022